JP6772065B2 - 免疫賦活プラスミド - Google Patents

免疫賦活プラスミド Download PDF

Info

Publication number
JP6772065B2
JP6772065B2 JP2016554261A JP2016554261A JP6772065B2 JP 6772065 B2 JP6772065 B2 JP 6772065B2 JP 2016554261 A JP2016554261 A JP 2016554261A JP 2016554261 A JP2016554261 A JP 2016554261A JP 6772065 B2 JP6772065 B2 JP 6772065B2
Authority
JP
Japan
Prior art keywords
composition
nucleic acid
sequence
immune response
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016554261A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017512202A5 (cg-RX-API-DMAC7.html
JP2017512202A (ja
Inventor
アイッカー，アンドレア
ヴェールマン，ヘルマン
ムンス，マルク
シャウアー，ロミーナ
アブラハム，アルバート
ヴァイス，クリスティアン
フェルトフース，エリザベス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Animal Health GmbH
Original Assignee
Bayer Animal Health GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Animal Health GmbH filed Critical Bayer Animal Health GmbH
Publication of JP2017512202A publication Critical patent/JP2017512202A/ja
Publication of JP2017512202A5 publication Critical patent/JP2017512202A5/ja
Application granted granted Critical
Publication of JP6772065B2 publication Critical patent/JP6772065B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16771—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2016554261A 2014-02-28 2015-02-27 免疫賦活プラスミド Expired - Fee Related JP6772065B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461946372P 2014-02-28 2014-02-28
US61/946,372 2014-02-28
PCT/EP2015/054131 WO2015128461A1 (en) 2014-02-28 2015-02-27 Immunostimulatory plasmids

Publications (3)

Publication Number Publication Date
JP2017512202A JP2017512202A (ja) 2017-05-18
JP2017512202A5 JP2017512202A5 (cg-RX-API-DMAC7.html) 2018-04-05
JP6772065B2 true JP6772065B2 (ja) 2020-10-21

Family

ID=52598746

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016554261A Expired - Fee Related JP6772065B2 (ja) 2014-02-28 2015-02-27 免疫賦活プラスミド

Country Status (20)

Country Link
US (2) US10155950B2 (cg-RX-API-DMAC7.html)
EP (1) EP3110940A1 (cg-RX-API-DMAC7.html)
JP (1) JP6772065B2 (cg-RX-API-DMAC7.html)
KR (1) KR20160122849A (cg-RX-API-DMAC7.html)
CN (1) CN106029867B (cg-RX-API-DMAC7.html)
AU (1) AU2015222102B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016019837A2 (cg-RX-API-DMAC7.html)
CA (1) CA2940794C (cg-RX-API-DMAC7.html)
CL (1) CL2016002146A1 (cg-RX-API-DMAC7.html)
CR (1) CR20160393A (cg-RX-API-DMAC7.html)
DO (1) DOP2016000223A (cg-RX-API-DMAC7.html)
IL (1) IL247065A0 (cg-RX-API-DMAC7.html)
MX (1) MX2016010993A (cg-RX-API-DMAC7.html)
PE (1) PE20170404A1 (cg-RX-API-DMAC7.html)
PH (1) PH12016501705A1 (cg-RX-API-DMAC7.html)
RU (1) RU2740492C2 (cg-RX-API-DMAC7.html)
SV (1) SV2016005263A (cg-RX-API-DMAC7.html)
UA (1) UA118374C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015128461A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201605495B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2016010993A (es) * 2014-02-28 2017-05-01 Bayer Animal Health Gmbh Plasmidos inmunoestimuladores.
WO2015187966A1 (en) 2014-06-04 2015-12-10 Aurasense Therapeutics, Llc Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
WO2016081911A2 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
MX2017017141A (es) * 2015-06-26 2018-03-09 Bayer Animal Health Gmbh Metodos de modulacion de moleculas de vigilancia de adn citosolicas.
WO2017021266A1 (en) * 2015-07-31 2017-02-09 Bayer Animal Health Gmbh Enhanced immune response in porcine species
AU2016304343A1 (en) * 2015-07-31 2018-02-08 Bayer Animal Health Gmbh Enhanced immune response in aquatic species
EP3490598A1 (en) 2016-07-26 2019-06-05 Bayer Animal Health GmbH Increased fertility in bovine species
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
CA3085661A1 (en) * 2017-12-15 2019-06-20 Bayer Animal Health Gmbh Immunostimulatory oligonucleotides
CN109646435B (zh) * 2019-01-11 2021-08-03 山东省农业科学院奶牛研究中心 厄他培南钠在制备防治牛传染性鼻气管炎药物中的应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5427791A (en) 1992-08-05 1995-06-27 Regents Of The University Of Minnesota Embryonal vaccine against Newcastle disease
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6645933B1 (en) * 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
US5830878A (en) 1995-06-07 1998-11-03 Megabios Corporation Cationic lipid: DNA complexes for gene targeting
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US6048535A (en) 1997-06-12 2000-04-11 Regents Of The University Of Minnesota Multivalent in ovo avian vaccine
US20040247662A1 (en) 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
DK1459766T3 (da) 1999-03-26 2008-10-13 Vical Inc Adjuvanssammensætninger til forstærkning af immunresponser på polynukleotidbaserede vacciner
US20040002472A1 (en) 2000-01-21 2004-01-01 Audonnet Jean-Christophe Francis Vaccination or immunization using a prime-boost regimen
US6517218B2 (en) 2000-03-31 2003-02-11 Relume Corporation LED integrated heat sink
US7238356B2 (en) * 2001-04-24 2007-07-03 Innogenetics N.V. Core-glycosylated HCV envelope proteins
CA2452666A1 (en) 2001-07-02 2003-01-16 Pfizer Products Inc. Mycoplasma hyopneumoniae vaccine and methods for reducing mycoplasma bovis pneumonia in cattle
AU2002953015A0 (en) * 2002-12-02 2002-12-12 Women's And Children's Hospital Modified lacz gene
US20070134200A1 (en) 2003-03-26 2007-06-14 Wyeth Immunogenic composition and methods
AU2004280143A1 (en) 2003-10-11 2005-04-21 Tekmira Pharmaceuticals Corporation Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
US20050181035A1 (en) 2004-02-17 2005-08-18 Dow Steven W. Systemic immune activation method using non CpG nucleic acids
EP1786461A4 (en) * 2004-08-13 2010-03-03 Univ Pennsylvania ANTIBIOTICINESIS-FREE DNA VACCINES
UY29915A1 (es) 2005-11-15 2007-06-29 Boehringer Ingelheim Vetmed Vacuna combinada que comprende un virus atenuado de la diarrea viral bovina
TWM297441U (en) 2006-03-30 2006-09-11 Cheng-Jiun Jian LED projection light source module
US7663229B2 (en) 2006-07-12 2010-02-16 Hong Kong Applied Science And Technology Research Institute Co., Ltd. Lighting device
CN101553498B (zh) * 2006-10-06 2012-08-08 斯克里普斯研究学院 用于引发对肿瘤相关巨噬细胞的免疫应答的dna组合物
WO2009046388A1 (en) * 2007-10-03 2009-04-09 United States Medical Research & Material Command Cr-2 binding peptide p28 as molecular adjuvant for dna vaccines
CA2719614C (en) 2008-03-25 2018-05-01 Juvaris Biotherapeutics, Inc. Enhancement of an immune response by administration of a cationic lipid-dna complex (cldc)
CN102202685A (zh) 2008-10-31 2011-09-28 贝林格尔.英格海姆维特梅迪卡有限公司 包含来自牛枝原体的抗原的多种抗原在多价疫苗组合物中的用途
US20120064151A1 (en) * 2009-05-14 2012-03-15 Bayer Animal Health Gmbh Enhanced immune response in avian species
JP6058550B2 (ja) 2010-12-22 2017-01-11 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ ウシの種における免疫応答の増強
CL2011000065A1 (es) 2011-01-11 2011-04-15 Univ Concepcion Formulacion veterinaria para la prevencion y eliminacion de infeccion por cepas de e. coli stec, que comprende un plasmido recombinante que codifica un factor de virulencia y liposoma cationico como vehiculo, uso de dicha formulacion para tratar preferentemente bovinos y porcinos.
MX2016010993A (es) * 2014-02-28 2017-05-01 Bayer Animal Health Gmbh Plasmidos inmunoestimuladores.

Also Published As

Publication number Publication date
CN106029867B (zh) 2020-02-14
AU2015222102A1 (en) 2016-08-18
RU2740492C2 (ru) 2021-01-14
CA2940794A1 (en) 2015-09-03
EP3110940A1 (en) 2017-01-04
KR20160122849A (ko) 2016-10-24
SV2016005263A (es) 2018-01-16
UA118374C2 (uk) 2019-01-10
CR20160393A (es) 2017-12-14
DOP2016000223A (es) 2016-09-30
RU2016138321A (ru) 2018-03-30
PH12016501705A1 (en) 2016-10-03
CA2940794C (en) 2022-05-31
US20180312842A1 (en) 2018-11-01
US10155950B2 (en) 2018-12-18
JP2017512202A (ja) 2017-05-18
IL247065A0 (en) 2016-09-29
WO2015128461A1 (en) 2015-09-03
MX2016010993A (es) 2017-05-01
BR112016019837A2 (pt) 2017-10-17
RU2016138321A3 (cg-RX-API-DMAC7.html) 2018-11-12
ZA201605495B (en) 2022-08-31
CL2016002146A1 (es) 2017-08-04
US20150267201A1 (en) 2015-09-24
PE20170404A1 (es) 2017-05-14
AU2015222102B2 (en) 2021-08-19
CN106029867A (zh) 2016-10-12
US10851379B2 (en) 2020-12-01

Similar Documents

Publication Publication Date Title
JP6772065B2 (ja) 免疫賦活プラスミド
RU2606855C2 (ru) Повышение иммунного отклика у видов крупного рогатого скота
EP2429581B1 (en) Enhanced immune response in avian species
EP3313376A2 (en) Methods of modulating cytosolic dna surveillance molecules
CN108025062A (zh) 猪科动物物种中增强的免疫应答
EP3328423B1 (en) Enhanced immune response in fish
TWI759317B (zh) 牛物種中增加的生育力
HK1229849B (zh) 免疫刺激性质粒
HK1229849A1 (en) Immunostimulatory plasmids
BR112018002107B1 (pt) Uso de um imunomodulador para potencializar resposta imune em espécies suínas

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180222

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190416

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191224

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200623

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200901

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200930

R150 Certificate of patent or registration of utility model

Ref document number: 6772065

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees